TransAct Technologies (NASDAQ:TACT – Get Free Report) and Amarillo Biosciences (OTCMKTS:AMAR – Get Free Report) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
Volatility and Risk
TransAct Technologies has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500.
Profitability
This table compares TransAct Technologies and Amarillo Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransAct Technologies | -0.75% | -1.25% | -0.85% |
| Amarillo Biosciences | -41,453.98% | N/A | -574.29% |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TransAct Technologies | $51.48 million | 1.04 | -$1.24 million | ($0.04) | -129.25 |
| Amarillo Biosciences | $20,000.00 | 0.00 | -$1.45 million | N/A | N/A |
TransAct Technologies has higher revenue and earnings than Amarillo Biosciences.
Analyst Recommendations
This is a summary of current ratings and price targets for TransAct Technologies and Amarillo Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TransAct Technologies | 1 | 1 | 0 | 0 | 1.50 |
| Amarillo Biosciences | 0 | 0 | 0 | 0 | 0.00 |
Given Amarillo Biosciences’ higher probable upside, analysts clearly believe Amarillo Biosciences is more favorable than TransAct Technologies.
Institutional and Insider Ownership
74.5% of TransAct Technologies shares are held by institutional investors. 19.2% of TransAct Technologies shares are held by company insiders. Comparatively, 34.4% of Amarillo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
TransAct Technologies beats Amarillo Biosciences on 7 of the 10 factors compared between the two stocks.
About TransAct Technologies
TransAct Technologies Incorporated designs, develops, and markets transaction-based and specialty printers and terminals in the United States and internationally. It offers thermal printers and terminals to generate labels, coupons, and transaction records, such as receipts, tickets, and other documents. The company also provides consumable products, including POS receipt paper, inkjet cartridges, ribbons, and other printing supplies, as well as replacement parts and accessories; and maintenance and repair services. In addition, it offers EPICENTRAL print system, a software solution that enables casino operators to create promotional coupons and marketing messages, and print them at the slot machine; and technical support services, as well as spare parts and accessories. Further, the company provides BOHA! terminal that combines hardware and software components in a device that includes an operating system, touchscreen, and one or two thermal print mechanisms. It markets its products under the TransAct, BOHA!, AccuDate, Ithaca, and EPICENTRAL brands for food service technology, point of sale automation, and casino and gaming markets. The company sells its products to original equipment manufacturers, value-added resellers, and distributors, as well as directly to end-users through its Webstore transactsupplies.com. TransAct Technologies Incorporated was incorporated in 1996 and is headquartered in Hamden, Connecticut.
About Amarillo Biosciences
Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.
Receive News & Ratings for TransAct Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransAct Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
